BR112022019423A2 - Moduladores de hemoglobina - Google Patents

Moduladores de hemoglobina

Info

Publication number
BR112022019423A2
BR112022019423A2 BR112022019423A BR112022019423A BR112022019423A2 BR 112022019423 A2 BR112022019423 A2 BR 112022019423A2 BR 112022019423 A BR112022019423 A BR 112022019423A BR 112022019423 A BR112022019423 A BR 112022019423A BR 112022019423 A2 BR112022019423 A2 BR 112022019423A2
Authority
BR
Brazil
Prior art keywords
hemoglobin
modulators
hemoglobin modulators
compounds
treatment
Prior art date
Application number
BR112022019423A
Other languages
English (en)
Inventor
Li Zhe
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of BR112022019423A2 publication Critical patent/BR112022019423A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MODULADORES DE HEMOGLOBINA. A presente invenção está relacionada geralmente a compostos e composições farmacêuticas adequados como moduladores de hemoglobina e métodos para seu uso no tratamento de distúrbios mediados por hemoglobina.
BR112022019423A 2020-03-31 2021-03-26 Moduladores de hemoglobina BR112022019423A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003104P 2020-03-31 2020-03-31
US202063003106P 2020-03-31 2020-03-31
PCT/US2021/024384 WO2021202284A1 (en) 2020-03-31 2021-03-26 Modulators of hemoglobin

Publications (1)

Publication Number Publication Date
BR112022019423A2 true BR112022019423A2 (pt) 2022-12-06

Family

ID=75562853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019423A BR112022019423A2 (pt) 2020-03-31 2021-03-26 Moduladores de hemoglobina

Country Status (5)

Country Link
US (1) US20230192611A1 (pt)
EP (1) EP4126832A1 (pt)
BR (1) BR112022019423A2 (pt)
CA (1) CA3176429A1 (pt)
WO (1) WO2021202284A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
WO2016043849A2 (en) * 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof

Also Published As

Publication number Publication date
CA3176429A1 (en) 2021-10-07
US20230192611A1 (en) 2023-06-22
EP4126832A1 (en) 2023-02-08
WO2021202284A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112014021269A2 (pt) "inibidores da beta-secretase, seus usos, e composição farmacêutica"
BR112014018475A8 (pt) Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112018011700A2 (pt) ?moduladores de canais de kv3 para tratar dor?
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
BR112021024117A2 (pt) Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
CO2022018636A2 (es) Moduladores de il-17a
CO2022016899A2 (es) Moduladores de il-17a
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112015004303A2 (pt) inibidores de beta-secretase
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
CO2023005057A2 (es) Compuestos y composiciones como moduladores de señalización tlr